Medigene AG provided earnings guidance for fiscal year 2022. The company maintains its guidance on expected revenues to be approximately EUR 30 million - EUR 32 million in 2022.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.473 EUR | +2.29% | -3.56% | -2.30% |
05-08 | Medigene Boosts Share Capital Via Rights Offering, Private Placement | MT |
05-02 | Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 - Targeted T Cell Receptor | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.30% | 38.09M | |
+3.91% | 109B | |
+10.87% | 105B | |
-0.09% | 22.25B | |
-13.14% | 22.09B | |
-8.17% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- MDG1 Stock
- News Medigene AG
- Medigene AG provides Earnings Guidance for Fiscal Year 2022